*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Ferrexpo announced a further delay to its annual results to give more time for an independent review of the company’s donations to the charity Blooming Land.
Rather than emerge with a full takeover bid, Sports Direct has prepared a template letter for other shareholders in Debenhams to use as part of boss Mike Ashley's push to install himself as chief executive of the troubled department store group.
AstraZeneca announced on Monday that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Therapy Designation’ for the MEK 1/2 inhibitor and potential new medicine selumetinib, which it is developing in partnership with Merck & Co.
